(Q28274460)

1

C Warren Olanow

0 references

Karl Kieburtz

4

Karl Kieburtz

0 references

Peter A. Lewitt

3

Peter A LeWitt

0 references

J P Hubble

8

Jean Hubble

0 references

author name string

Dirk Sauer

5

0 references

Gianfranco Olivieri

6

0 references

Harald Pohlmann

Parkinson's disease. First of two parts

7

0 references

language of work or name

English

0 references

publication date

December 2006

0 references

published in

Lancet Neurology

0 references

volume

5

0 references

issue

12

0 references

page(s)

1013-20

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Neuropathology of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

The scientific basis for the current treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Symptomatic and neuroprotective properties of the aliphatic propargylamines

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Parkinsonism: onset, progression, and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Assuring interrater reliability for the UPDRS motor section: utility of the UPDRS teaching tape.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

A role for GAPDH in apoptosis and neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Dopaminergic neurons degenerate by apoptosis in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Increased expression and redistribution of the antiapoptotic molecule Bcl-xL in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Experimental models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Altered proteasomal function in sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Proteasome inhibitor-induced model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Lack of nigrostriatal pathology in a rat model of proteasome inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Proteasome inhibition and Parkinson's disease modeling

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Molecular pathophysiology of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970602-0

7 January 2021

10.1016/S1474-4422(06)70602-0

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

959332

959332

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference